JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Neurology

Neurology antibodies target proteins involved in neurodegeneration, neuropathic pain and migraine signaling. Aducanumab, gantenerumab and donanemab bind aggregated forms of amyloid beta (Aβ), each with a different preference for oligomers, fibrils or plaque species. Fremanezumab and galcanezumab neutralize calcitonin gene-related peptide (CGRP), whereas erenumab blocks the CGRP receptor. Tanezumab neutralizes nerve growth factor (NGF), a key mediator of nociceptor sensitization in inflammatory pain models. Further antibodies bind tau, alpha-synuclein and axon-growth inhibitors such as myelin-associated glycoprotein and repulsive guidance molecule A.

Cat. No.

AT0696

CAS No.

2966023-63-0

ARGX-119

ARGX-119 is a pioneering humanized agonist monoclonal antibody that selectively targets muscle-specific kinase (MuSK). This antibody is particularly useful for the investigation of neuromuscular diseases, providing a critical tool for understanding the pathophysiology and potential therapeutic interventions in these disorders. For isotype control purposes, researchers should use Human IgG1 lambda1, Isotype Control, which serves as a standard for experimental consistency and validation.

In stock View Details

1 mg

$450.00

5 mg

$1,400.00

All 3 sizes

Neurology

ARGX-119